Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
62
CRSP Quote, Financials, Valuation and Earnings
Last price:
$53.36
Seasonality move
:
1.96%
Day range:
$52.00 - $54.70
52-week range:
$30.04 - $78.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,399.40x
P/B ratio:
2.73x
Volume:
984.2K
Avg. volume:
1.7M
1-year change:
3.06%
Market cap:
$5.2B
Revenue:
$3.5M
EPS (TTM):
-$6.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
$4M | -$1.23 | 430.19% | -22.57% | $84.78 |
|
BEAM
Beam Therapeutics, Inc.
|
$13.2M | -$1.11 | 84.01% | -6.81% | $47.21 |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
NVS
Novartis AG
|
$14.1B | $2.00 | 3.1% | 9.19% | $139.80 |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$3.2B | $5.15 | 11.14% | 76.99% | $530.70 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
$54.64 | $84.78 | $5.2B | -- | $0.00 | 0% | 1,399.40x |
|
BEAM
Beam Therapeutics, Inc.
|
$27.88 | $47.21 | $2.8B | -- | $0.00 | 0% | 46.97x |
|
CSBTF
Kuros Biosciences Ltd.
|
$32.00 | -- | $1.3B | -- | $0.00 | 0% | 9.78x |
|
ELVAF
EvoNext Holdings SA
|
$1.1000 | -- | $7.9M | 5.90x | $0.00 | 0% | 0.61x |
|
NVS
Novartis AG
|
$163.92 | $139.80 | $312.8B | 22.81x | $3.99 | 2.44% | 5.85x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$469.27 | $530.70 | $119.2B | 30.60x | $0.00 | 0% | 10.03x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
9.71% | 2.738 | 4.11% | 13.30x |
|
BEAM
Beam Therapeutics, Inc.
|
13.55% | 1.861 | 6.16% | 5.89x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.224 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.210 | -- | -- |
|
NVS
Novartis AG
|
43.4% | -0.357 | 13.43% | 0.75x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
9.84% | -0.890 | 1.77% | 2.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
-$58.5M | -$154.8M | -28% | -31.24% | -17912.5% | -$93.1M |
|
BEAM
Beam Therapeutics, Inc.
|
$4.1M | -$126.8M | -38.05% | -44.48% | -1307.6% | -$86.5M |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
NVS
Novartis AG
|
$9.8B | $3.5B | 18.52% | 32.47% | 26.4% | $1.2B |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$2.8B | $1.3B | 20.84% | 22.97% | 40.3% | $348.6M |
CRISPR Therapeutics AG vs. Competitors
-
Which has Higher Returns CRSP or BEAM?
Beam Therapeutics, Inc. has a net margin of -15117.25% compared to CRISPR Therapeutics AG's net margin of -1162.38%. CRISPR Therapeutics AG's return on equity of -31.24% beat Beam Therapeutics, Inc.'s return on equity of -44.48%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6770.83% -$1.37 $2.1B BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B -
What do Analysts Say About CRSP or BEAM?
CRISPR Therapeutics AG has a consensus price target of $84.78, signalling upside risk potential of 55.17%. On the other hand Beam Therapeutics, Inc. has an analysts' consensus of $47.21 which suggests that it could grow by 69.35%. Given that Beam Therapeutics, Inc. has higher upside potential than CRISPR Therapeutics AG, analysts believe Beam Therapeutics, Inc. is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG13 9 1 BEAMBeam Therapeutics, Inc.13 2 0 -
Is CRSP or BEAM More Risky?
CRISPR Therapeutics AG has a beta of 1.724, which suggesting that the stock is 72.403% more volatile than S&P 500. In comparison Beam Therapeutics, Inc. has a beta of 2.116, suggesting its more volatile than the S&P 500 by 111.58%.
-
Which is a Better Dividend Stock CRSP or BEAM?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beam Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Beam Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or BEAM?
CRISPR Therapeutics AG quarterly revenues are $864K, which are smaller than Beam Therapeutics, Inc. quarterly revenues of $9.7M. CRISPR Therapeutics AG's net income of -$130.6M is lower than Beam Therapeutics, Inc.'s net income of -$112.7M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Beam Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 1,399.40x versus 46.97x for Beam Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG1,399.40x -- $864K -$130.6M BEAMBeam Therapeutics, Inc.46.97x -- $9.7M -$112.7M
-
Which has Higher Returns CRSP or CSBTF?
Kuros Biosciences Ltd. has a net margin of -15117.25% compared to CRISPR Therapeutics AG's net margin of --. CRISPR Therapeutics AG's return on equity of -31.24% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6770.83% -$1.37 $2.1B CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About CRSP or CSBTF?
CRISPR Therapeutics AG has a consensus price target of $84.78, signalling upside risk potential of 55.17%. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CRISPR Therapeutics AG has higher upside potential than Kuros Biosciences Ltd., analysts believe CRISPR Therapeutics AG is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG13 9 1 CSBTFKuros Biosciences Ltd.0 0 0 -
Is CRSP or CSBTF More Risky?
CRISPR Therapeutics AG has a beta of 1.724, which suggesting that the stock is 72.403% more volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.678%.
-
Which is a Better Dividend Stock CRSP or CSBTF?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or CSBTF?
CRISPR Therapeutics AG quarterly revenues are $864K, which are larger than Kuros Biosciences Ltd. quarterly revenues of --. CRISPR Therapeutics AG's net income of -$130.6M is higher than Kuros Biosciences Ltd.'s net income of --. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 1,399.40x versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG1,399.40x -- $864K -$130.6M CSBTFKuros Biosciences Ltd.9.78x -- -- --
-
Which has Higher Returns CRSP or ELVAF?
EvoNext Holdings SA has a net margin of -15117.25% compared to CRISPR Therapeutics AG's net margin of --. CRISPR Therapeutics AG's return on equity of -31.24% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6770.83% -$1.37 $2.1B ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About CRSP or ELVAF?
CRISPR Therapeutics AG has a consensus price target of $84.78, signalling upside risk potential of 55.17%. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that CRISPR Therapeutics AG has higher upside potential than EvoNext Holdings SA, analysts believe CRISPR Therapeutics AG is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG13 9 1 ELVAFEvoNext Holdings SA0 0 0 -
Is CRSP or ELVAF More Risky?
CRISPR Therapeutics AG has a beta of 1.724, which suggesting that the stock is 72.403% more volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -42.013, suggesting its less volatile than the S&P 500 by 4301.301%.
-
Which is a Better Dividend Stock CRSP or ELVAF?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or ELVAF?
CRISPR Therapeutics AG quarterly revenues are $864K, which are larger than EvoNext Holdings SA quarterly revenues of --. CRISPR Therapeutics AG's net income of -$130.6M is higher than EvoNext Holdings SA's net income of --. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 1,399.40x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG1,399.40x -- $864K -$130.6M ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns CRSP or NVS?
Novartis AG has a net margin of -15117.25% compared to CRISPR Therapeutics AG's net margin of 18.03%. CRISPR Therapeutics AG's return on equity of -31.24% beat Novartis AG's return on equity of 32.47%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6770.83% -$1.37 $2.1B NVSNovartis AG73.44% $1.25 $81.9B -
What do Analysts Say About CRSP or NVS?
CRISPR Therapeutics AG has a consensus price target of $84.78, signalling upside risk potential of 55.17%. On the other hand Novartis AG has an analysts' consensus of $139.80 which suggests that it could fall by -14.71%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG13 9 1 NVSNovartis AG1 5 3 -
Is CRSP or NVS More Risky?
CRISPR Therapeutics AG has a beta of 1.724, which suggesting that the stock is 72.403% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.508, suggesting its less volatile than the S&P 500 by 49.176%.
-
Which is a Better Dividend Stock CRSP or NVS?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 2.44% to investors and pays a quarterly dividend of $3.99 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Novartis AG pays out 42.8% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRSP or NVS?
CRISPR Therapeutics AG quarterly revenues are $864K, which are smaller than Novartis AG quarterly revenues of $13.3B. CRISPR Therapeutics AG's net income of -$130.6M is lower than Novartis AG's net income of $2.4B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Novartis AG's PE ratio is 22.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 1,399.40x versus 5.85x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG1,399.40x -- $864K -$130.6M NVSNovartis AG5.85x 22.81x $13.3B $2.4B
-
Which has Higher Returns CRSP or VRTX?
Vertex Pharmaceuticals, Inc. has a net margin of -15117.25% compared to CRISPR Therapeutics AG's net margin of 36.91%. CRISPR Therapeutics AG's return on equity of -31.24% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6770.83% -$1.37 $2.1B VRTXVertex Pharmaceuticals, Inc.85.56% $4.65 $20.7B -
What do Analysts Say About CRSP or VRTX?
CRISPR Therapeutics AG has a consensus price target of $84.78, signalling upside risk potential of 55.17%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $530.70 which suggests that it could grow by 13.09%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG13 9 1 VRTXVertex Pharmaceuticals, Inc.21 5 1 -
Is CRSP or VRTX More Risky?
CRISPR Therapeutics AG has a beta of 1.724, which suggesting that the stock is 72.403% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.
-
Which is a Better Dividend Stock CRSP or VRTX?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or VRTX?
CRISPR Therapeutics AG quarterly revenues are $864K, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. CRISPR Therapeutics AG's net income of -$130.6M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 30.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 1,399.40x versus 10.03x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG1,399.40x -- $864K -$130.6M VRTXVertex Pharmaceuticals, Inc.10.03x 30.60x $3.2B $1.2B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
